findmyKOL
Clinical trialNCT00006268CompletedPhase 1/PHASE2Interventional

Immunotoxin Therapy in Treating Patients With Malignant Glioma

SponsorNew Approaches to Brain Tumor Therapy ConsortiumBrain and Central Nervous System Tumors
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for malignant glioma. PURPOSE: Phase I/II trial to study the effectiveness of immunotoxin therapy in treating patients who have malignant glioma.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham Comprehensive Cancer Center

    Birmingham, Alabama, United States

  • H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

    Tampa, Florida, United States

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, United States

  • National Institute of Neurological Disorders and Stroke

    Bethesda, Maryland, United States

  • Warren Grant Magnuson Clinical Center - Nci Clinical Studies Support

    Bethesda, Maryland, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, United States

  • Josephine Ford Cancer Center at Henry Ford Health System

    Detroit, Michigan, United States

  • Comprehensive Cancer Center at Wake Forest University

    Winston-Salem, North Carolina, United States

  • Abramson Cancer Center at the University of Pennsylvania

    Philadelphia, Pennsylvania, United States

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cintredekin besudotoxIsolated perfusion
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2000
Primary completion
—
Completion
31 Mar 2005
Last update posted
24 Jun 2013
Registered enrollment
—
Registry id
NCT00006268
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.